13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q1 2024 · Filed May 14, 2024 · Accession 0000950123-24-005045
Total Value
$155.0M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Nuvation Bio | NUVB | 14,072,340 | $51.2M | 33.05% |
| 2 | Lexeo Therapeutics | LXEO | 2,355,904 | $36.9M | 23.83% |
| 3 | Replimune Group | REPL | 3,001,319 | $24.5M | 15.82% |
| 4 | enGene Holdings Inc. | ENGNW | 1,076,357 | $18.2M | 11.77% |
| 5 | Sana Biotechnology, Inc. | SANA | 843,750 | $8.4M | 5.44% |
| 6 | Morphic Holding | 61775R105 | 159,846 | $5.6M | 3.63% |
| 7 | Ikena Oncology | 45175G108 | 2,249,123 | $3.2M | 2.06% |
| 8 | Immunic Inc | IMUX | 1,788,160 | $2.4M | 1.52% |
| 9 | enGene Holdings Inc. | ENGNW | 360,903 | $1.9M | 1.21% |
| 10 | Syros Pharmaceuticals | 87184Q206 | 251,270 | $1.3M | 0.87% |
| 11 | Kronos Bio | 50107A104 | 955,866 | $1.2M | 0.80% |